NASDAQ:FBIO Fortress Biotech (FBIO) Stock Price, News & Analysis → The World’s Richest Man Blindsided by AI (From Banyan Hill Publishing) (Ad) Free FBIO Stock Alerts $1.77 +0.07 (+4.12%) (As of 02:13 PM ET) Add Compare Share Share Today's Range$1.66▼$1.7950-Day Range$1.67▼$2.2752-Week Range$1.24▼$11.25Volume110,742 shsAverage Volume356,094 shsMarket Capitalization$34.05 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Fortress Biotech alerts: Email Address Fortress Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,644.2% Upside$30.00 Price TargetShort InterestBearish12.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.57) to ($5.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.42 out of 5 starsMedical Sector1509th out of 2,771 stocksPharmaceutical Preparations Industry701st out of 1,288 stocks 3.5 Analyst's Opinion Consensus RatingFortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFortress Biotech has only been the subject of 2 research reports in the past 90 days.Read more about Fortress Biotech's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.69% of the float of Fortress Biotech has been sold short.Short Interest Ratio / Days to CoverFortress Biotech has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Fortress Biotech has recently decreased by 3.85%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldFortress Biotech does not currently pay a dividend.Dividend GrowthFortress Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FBIO. Previous Next 1.9 News and Social Media Coverage News SentimentFortress Biotech has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Fortress Biotech this week, compared to 1 article on an average week.Search InterestOnly 14 people have searched for FBIO on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fortress Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders33.40% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fortress Biotech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fortress Biotech are expected to grow in the coming year, from ($6.57) to ($5.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fortress Biotech is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fortress Biotech is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFortress Biotech has a P/B Ratio of 17.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Fortress Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden FINISHED On June 13th?Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered.Click here now to see his shocking evidence. About Fortress Biotech Stock (NASDAQ:FBIO)Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Read More FBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FBIO Stock News HeadlinesMay 14 at 8:30 AM | globenewswire.comFortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver TransplantationMay 13 at 4:01 PM | globenewswire.comJourney Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 13 at 8:30 AM | globenewswire.comCheckpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 10, 2024 | globenewswire.comCheckpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesMay 7, 2024 | globenewswire.comJourney Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024May 1, 2024 | globenewswire.comJourney Medical Corporation Appoints Joseph Benesch as Chief Financial OfficerApril 25, 2024 | globenewswire.comJourney Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024April 11, 2024 | investorplace.com3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024March 29, 2024 | finanznachrichten.deFortress Biotech, Inc.: Fortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsMarch 28, 2024 | globenewswire.comFortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsMarch 28, 2024 | finanznachrichten.deMustang Bio, Inc.: Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesMarch 28, 2024 | msn.comMustang Bio stock climbs 9% amid drug development updateMarch 22, 2024 | globenewswire.comCheckpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsMarch 21, 2024 | globenewswire.comJourney Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsMarch 18, 2024 | finance.yahoo.comAvenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsMarch 18, 2024 | globenewswire.comJourney Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of RosaceaMarch 15, 2024 | globenewswire.comJourney Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024March 13, 2024 | globenewswire.comJourney Medical Corporation to Participate in the 36th Annual ROTH ConferenceMarch 12, 2024 | globenewswire.comFortress Biotech to Participate in 36th Annual ROTH ConferenceMarch 11, 2024 | globenewswire.comJourney Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual MeetingMarch 4, 2024 | globenewswire.comFortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes DiseaseJanuary 29, 2024 | finance.yahoo.comCheckpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-MarketJanuary 11, 2024 | finance.yahoo.comAvenue Therapeutics to Present at Sidoti January Micro-Cap Investor ConferenceJanuary 9, 2024 | finance.yahoo.comInsider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ...January 5, 2024 | finance.yahoo.comJourney Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat RosaceaSee More Headlines Receive FBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/14/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:FBIO CUSIP21976U10 CIK1429260 Webwww.fortressbiotech.com Phone(781) 652-4500Fax781-652-4545Employees187Year FoundedN/APrice Target and Rating Average Stock Price Target$30.00 High Stock Price Target$75.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,685.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($8.2166) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,640,000.00 Net Margins-74.12% Pretax Margin-181.79% Return on Equity-770.86% Return on Assets-32.87% Debt Debt-to-Equity Ratio38.42 Current Ratio1.38 Quick Ratio1.26 Sales & Book Value Annual Sales$84.51 million Price / Sales0.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book16.80Miscellaneous Outstanding Shares19,240,000Free Float12,811,000Market Cap$32.32 million OptionableOptionable Beta1.56 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Lindsay Allan Rosenwald (Age 69)Executive Chairman, President & CEO Comp: $942.78kMr. Michael S. Weiss Esq. (Age 58)Vice Chairman & Executive Vice Chairman of Strategic Development Comp: $167.92kMr. David Jin (Age 33)CFO & Head of Corporate Development Comp: $976.96kDr. George C. Avgerinos (Age 70)Senior Vice President of Biologics Operations Comp: $386.49kMr. Samuel BerryGeneral Counsel & Corporate SecretaryKey CompetitorsBolt BiotherapeuticsNASDAQ:BOLTMolecular TemplatesNASDAQ:MTEMBriaCell TherapeuticsNASDAQ:BCTXImmunoPrecise AntibodiesNASDAQ:IPASpruce BiosciencesNASDAQ:SPRBView All CompetitorsInsiders & InstitutionsAcadian Asset Management LLCBought 161,870 shares on 5/10/2024Ownership: 1.518%Shikiar Asset Management Inc.Bought 40,000 shares on 4/22/2024Ownership: 1.160%PFG Investments LLCBought 16,291 shares on 4/22/2024Ownership: 0.085%B. Riley Wealth Advisors Inc.Sold 58,725 shares on 3/15/2024Ownership: 0.962%PVG Asset Management CorpBought 131,490 shares on 3/12/2024Ownership: 1.471%View All Insider TransactionsView All Institutional Transactions FBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Fortress Biotech stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FBIO shares. View FBIO analyst ratings or view top-rated stocks. What is Fortress Biotech's stock price target for 2024? 3 equities research analysts have issued 12 month target prices for Fortress Biotech's stock. Their FBIO share price targets range from $5.00 to $75.00. On average, they anticipate the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 1,644.2% from the stock's current price. View analysts price targets for FBIO or view top-rated stocks among Wall Street analysts. How have FBIO shares performed in 2024? Fortress Biotech's stock was trading at $3.01 at the beginning of 2024. Since then, FBIO shares have decreased by 42.9% and is now trading at $1.72. View the best growth stocks for 2024 here. When is Fortress Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our FBIO earnings forecast. How were Fortress Biotech's earnings last quarter? Fortress Biotech, Inc. (NASDAQ:FBIO) announced its quarterly earnings results on Thursday, March, 28th. The biopharmaceutical company reported ($0.53) EPS for the quarter. The biopharmaceutical company earned $19.95 million during the quarter, compared to analysts' expectations of $14.46 million. Fortress Biotech had a negative net margin of 74.12% and a negative trailing twelve-month return on equity of 770.86%. When did Fortress Biotech's stock split? Fortress Biotech's stock reverse split on the morning of Tuesday, October 10th 2023. The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Fortress Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX). Who are Fortress Biotech's major shareholders? Fortress Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (1.52%), Shikiar Asset Management Inc. (1.16%) and PFG Investments LLC (0.08%). Insiders that own company stock include Lindsay A Md Rosenwald and Michael S Weiss. View institutional ownership trends. How do I buy shares of Fortress Biotech? Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FBIO) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.